Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 1, 1996, Pages 24-28

  Rapeport, William G ^a   Muirhead, David C ^a   Williams, Stephen A ^a   Cross, Maurice ^b   Wesnes, Keith ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Phase I Clinical Trials Unit   (United Kingdom)

^c Cognitive Drug Research ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; SERTRALINE;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

1-NAPHTHYLAMINE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; PLACEBOS; PSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; REACTION TIME; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0030002395     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Rall TW. Schleifer LS, Drugs effective in the therapy of the epilepsies. In: Goodman AG, Rall TW, Nies AS, et al, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY: Pergamon Press: 1990:436-462
2. Drug Facts and Comparisons. St Louis, Mo: Facts and Comparisons Inc; 1994:282d-283b
3. Preskorn SH. Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant J Clin Psychiatry 1992:53(9, suppl): 5-18
4. Grimsley SR. Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930-957
5. DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992:53(2, suppl):13-20
6. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993:24:203-220
7. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment, J Clin Psychiatry 1993:54(9, suppl):14-34
8. Preskorn S. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. Int Clin Psychopharmacol 1994;9(suppl 3): 13-19
9. Brøsen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990:18:220-239
10. Otton SV, Wu D. Joffe RT. et al. Inhibition by fluoxerine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993:53:401-409
11. von Moltke LL, Greenblatt DJ. Cotreau-Bibbo MM, et al. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994:268:1278-1283
12. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole, and quinidine. Br J Clin Pharmacol 1994:38: 23-31
13. Lasher TA, Fleishaker JC. SteenwykRC, et al. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology (Berl) 1991:104:323-327
14. Greenblatt DJ. Preskom SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not clonazepam. Clin Pharmacol Ther 1992;52: 479-486
15. Lemberger L, Rowe H. Bosomworth JC, et al. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988:43:412-419
16. Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1993;45:1211-1214
17. Tremaine LM. Wilner KD, Henry EB, et al. Absence of a biologically meaningful effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet. In press
18. Wilner KD, Apseloff G. Gerber N, et al. Absence of a biologically meaningful effect of sertraline on the pharmacodynamics and protein binding of warfarin, Clin Pharmacokinet. In press
19. von Moltke LL, Greenblatt DJ, Shader RL Predictable and modest inhibition of desipramine clearance by sertraline at low and high doses. Presented at the 148th annual meeting of the American Psychiatric Association; May 20-25, 1995; Miami, Fla
20. van Harten J, Stevens L. Raghoebar M. et al. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther 1992;52:427-135
21. Wesnes K, Simpson PM, Kidd AG. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg. Human Psychopharmacology 1988;3:27-43
22. Brickenkamp R. Test d2 Aufmerksamkeits-Belasrungs-Test Handanweisung. Gottingen, Germany: Verlag fur Psychologie Dr. C. J. Hogrefe; 1981
23. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974:47:211-218
24. Preskorn S. Lane R. 50 mg/day as the optimum dose for sertraline. Int Clin Psychopharmacol, In press
25. Shader RI, Greenblatt DJ, von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994;14:375-376
26. Campbell ME, Grant DM, Inaba T, et al Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Disp 1987:15:237-248
27. Crowley JJ, Cusack BJ, Jue SG, et al. Aging and drug interactions, II: effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men. J Pharmacol Exp Ther 1988; 245:513-523